Back to search results
NCT07354412

Investigating Cannabis Use Parameters on Anesthesia and Inflammation in Lumbar Spinal Surgeries

Enrolling by Invitation
Not specifiedAges 18+Observational
University of Missouri-Columbia
~210 participants
Updated 2026-01-21 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Intraoperative Propofol dose (mg/kg/hr)
Measured over Duration of surgery
+4 more outcomes measured

Conditions

Cannabis Use

Explore related trials

Lumbar Spinal Surgery

Where it's being run

2 sites across 1 states
Missouri2

Study leadership

  • Antoinette Burger, PhD · STUDY_DIRECTOR · University of Missouri-Columbia
  • Randi Foraker, PhD · STUDY_DIRECTOR · University of Missouri-Columbia

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Undergoing ambulatory or short-stay lumbar spine surgery.
English speaking.
Ability to consent for themselves.
Aged 18 years and above.
Access to a smartphone or computer/laptop (to be determined on the day of consent).

Exclusion

Non-English speaking.
Inability to consent for themselves.
Actively pregnant (SOC) or planning to become pregnant in the next 2 months (research only). Urine testing will be done as SOC prior to undergoing surgery.
Active or past severe psychiatric instability (e.g., active psychosis, acute suicidality)
Active, uncontrolled use of illicit drugs use such as methamphetamine, cocaine, opioids, etc., as listed in their clinical charts.
History of major neurological illnesses.
Presence of an untreated illness or serious medical condition.
Any other concern that in the investigator's opinion would impact participant safety, study instruction compliance, or confound the interpretation of the study results.
No access to a smartphone or computer/laptop.

What this trial measures

  • Intraoperative Propofol dose (mg/kg/hr)Duration of surgery

    Our primary outcome is intraoperative anesthetic dose (i.e., propofol mg/kg/hr), which will be extracted from anesthesia records and entered into each patient's individual REDCap record by the study personnel.

  • Change in serum inflammatory biomarker IL-2 (pg/mL)From enrollment to 6 week post-surgery

    The investigators will measure serum biomarker of inflammation IL-2 (pg/mL) before and after surgery, and again at 2- and 6-week follow-ups, to assess how cannabis exposure modulates immune responses.

  • Change in serum inflammatory biomarker IL-6 (pg/mL)From enrollment to 6 week post-surgery

    The investigators will measure serum biomarker of inflammation IL-6 (pg/mL) before and after surgery, and again at 2- and 6-week follow-ups, to assess how cannabis exposure modulates immune responses.

  • Change in serum inflammatory biomarker TNF-α (pg/mL)From enrollment to 6 week post-surgery

    The investigators will measure serum biomarker of inflammation TNF-α (pg/mL) before and after surgery, and again at 2- and 6-week follow-ups, to assess how cannabis exposure modulates immune responses.

  • Change in serum inflammatory biomarker CRP (pg/mL)From enrollment to 6 week post-surgery

    The investigators will measure serum biomarker of inflammation CRP (pg/mL) before and after surgery, and again at 2- and 6-week follow-ups, to assess how cannabis exposure modulates immune responses.